A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis
To observe the efficacy of Trilaciclib combined with lateral ventricular chemotherapy in the treatment of non-small cell lung cancer with leptomeningeal metastasisã€‚
NSCLC
DRUG: combination of Trilaciclib and Pemetrexed
Duration of severe neutropenia (DSN), Duration of severe neutropenia in cycle 1, During Trilaciclib plus chemotherapy assessed up to 21 days
Incidence of Treatment-Emergent Adverse Events, Occurrence and severity of AEs by NCI CTCAE v5.0, Up to 2 years|Incidence of grade 3 and 4 hematologic toxicity, Incidence of grade 3 and 4 hematologic toxicity, during Trilaciclib plus chemotherapy assessed up to 1 years|Incidence of G-CSF treatment, Incidence of G-CSF treatment, during Trilaciclib plus chemotherapy assessed up to 1 years|Incidence of platelet transfusion, Incidence of platelet transfusion, during Trilaciclib plus chemotherapy assessed up to 1 years
A single-arm, open-label, interventional study was conducted in 25 NSCLC patients with leptomeningeal metastases to observe the efficacy of Trilaciclib combined with lateral ventricular chemotherapy in the treatment of non-small cell lung cancer with leptomeningeal metastases, and to evaluate the incidence and duration of severe neutropenia in the first cycle.